Corvus Pharmaceuticals Begins Phase 1b Trial of Soquelitinib for Hidradenitis Suppurativa

Corvus Pharmaceuticals has commenced enrollment for a Phase 1b clinical trial of its oral soquelitinib treatment for moderate to severe hidradenitis suppurativa. The trial will enroll up to 25 patients who will receive 200 mg of soquelitinib twice daily for 12 weeks. The primary endpoint is safety, with key efficacy endpoints including HiSCR 50/75 at week 12.